[go: up one dir, main page]

GB201115977D0 - Neurodevelopmental disorders - Google Patents

Neurodevelopmental disorders

Info

Publication number
GB201115977D0
GB201115977D0 GBGB1115977.9A GB201115977A GB201115977D0 GB 201115977 D0 GB201115977 D0 GB 201115977D0 GB 201115977 A GB201115977 A GB 201115977A GB 201115977 D0 GB201115977 D0 GB 201115977D0
Authority
GB
United Kingdom
Prior art keywords
neurodevelopmental disorders
methods
disorders
ameliorating
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1115977.9A
Other versions
GB2503187A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sussex
Original Assignee
University of Sussex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sussex filed Critical University of Sussex
Priority to GB1115977.9A priority Critical patent/GB2503187A/en
Publication of GB201115977D0 publication Critical patent/GB201115977D0/en
Priority to PCT/GB2012/052278 priority patent/WO2013038200A2/en
Publication of GB2503187A publication Critical patent/GB2503187A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides pharmaceutical compositions, medicaments and methods for use in preventing, ameliorating or treating neurodevelopmental disorders. The invention extends to novel synthetic methods for preparing active agents useful in the treatment of neurodevelopmental disorders.
GB1115977.9A 2011-09-15 2011-09-15 Composition for use in the treatment of neurodevelopmental disorders Withdrawn GB2503187A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1115977.9A GB2503187A (en) 2011-09-15 2011-09-15 Composition for use in the treatment of neurodevelopmental disorders
PCT/GB2012/052278 WO2013038200A2 (en) 2011-09-15 2012-09-14 Neurodevelopmental disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1115977.9A GB2503187A (en) 2011-09-15 2011-09-15 Composition for use in the treatment of neurodevelopmental disorders

Publications (2)

Publication Number Publication Date
GB201115977D0 true GB201115977D0 (en) 2011-10-26
GB2503187A GB2503187A (en) 2013-12-25

Family

ID=44908638

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1115977.9A Withdrawn GB2503187A (en) 2011-09-15 2011-09-15 Composition for use in the treatment of neurodevelopmental disorders

Country Status (2)

Country Link
GB (1) GB2503187A (en)
WO (1) WO2013038200A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3261645T (en) 2015-02-27 2021-06-17 Dechra Ltd Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
WO2017083739A1 (en) 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
EP3856156A2 (en) * 2018-09-28 2021-08-04 Medizinische Hochschule Hannover (MHH) 5-ht7 antagonist for the treatment of dementia-associated tauopathies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3760089A (en) 1972-04-27 1973-09-18 Westinghouse Electric Corp Electrical bushing assembly having resilient means enclosed within sealing means
DE3579189D1 (en) 1984-04-24 1990-09-20 Glaxo Group Ltd HETEROCYCLIC AMINO COMPOUNDS.
GB8526209D0 (en) 1985-10-23 1985-11-27 Glaxo Group Ltd Chemical process
GB8828032D0 (en) * 1988-12-01 1989-01-05 Glaxo Group Ltd Medicaments
GB8911166D0 (en) * 1989-05-16 1989-07-05 Glaxo Group Ltd Medicaments
GB2244431A (en) * 1990-05-31 1991-12-04 Farmos Oy Treatment of age related memory impairment and other cognitive disorders
GB9012469D0 (en) * 1990-06-05 1990-07-25 Glaxo Group Ltd Medicaments
GB9119466D0 (en) 1991-09-12 1991-10-23 Glaxo Group Ltd Chemical compounds
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB0002100D0 (en) * 2000-01-28 2000-03-22 Novartis Ag Organic compounds
US7592350B2 (en) * 2002-04-03 2009-09-22 Orion Corporation Polycyclic compounds as potent alpha2-adrenoceptor antagonists
CA2494109A1 (en) * 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood

Also Published As

Publication number Publication date
WO2013038200A3 (en) 2013-06-27
GB2503187A (en) 2013-12-25
WO2013038200A2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
IN2014DN09434A (en)
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX343687B (en) Tricyclic sulfonamide compounds and methods of making and using same.
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2014008705A (en) Tricyclic sulfone compounds and methods of making and using same.
MX365939B (en) Nuclear transport modulators and uses thereof.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2014008706A (en) Tricyclic sulfonamide compounds and methods of making and using same.
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
MX2015005733A (en) Tricyclic compounds for use in the treatment and/or control of obesity.
MX364528B (en) Withanolides useful for the treatment of neurodegenerative diseases.
GB201115977D0 (en) Neurodevelopmental disorders
MX369774B (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders.
MX2015001670A (en) Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof.
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
IN2013MU01240A (en)
IN2013MU01241A (en)
IN2013MU01242A (en)
IN2013MU01239A (en)
IN2013MU01251A (en)
IN2013MU01244A (en)

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)